-+ 0.00%
-+ 0.00%
-+ 0.00%

Innate Pharma to present MATISSE Phase 2 interim IPH5201 results at AACR 2026

PUBT·04/17/2026 19:00:39
Listen to the news
Innate Pharma to present MATISSE Phase 2 interim IPH5201 results at AACR 2026
  • Innate Pharma set interim Phase 2 MATISSE results for IPH5201 in resectable non-small cell lung cancer for presentation at AACR 2026 on April 21.
  • Pre-planned interim analysis indicated combination regimen delivered a stronger tumor clearance signal than durvalumab with chemotherapy benchmark.
  • Company kept trial enrollment focused on patients with PD-L1-positive tumors based on interim findings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260417313341) on April 17, 2026, and is solely responsible for the information contained therein.